Novo Nordisk (NVO) is down 40% year-over-year while Eli Lilly (LLY) is up 30%. It's a shake-up in the GLP-1 trade that few expected, especially with Matt Maley pointing out that Novo Nordisk originally had the market lead. He talks about how Eli Lilly capitalized on competitor weaknesses through Zepbound and Mounjaro. One warning from Matt: "don't be afraid to buy both stocks," just do it through nibbles. He points to Eli Lilly's substantial P/E ratio and Novo Nordisk's anemic metric.